Score Your Stock

US stock · figures in US dollars · scored on full-year results

Illumina Illumina, Inc.

ILMN · Healthcare · Diagnostics & Research
Bottom 36% of scored stocks
OkayBottom 36% of scored stocks
Weak SpotProfit SpikeRecent Loss

Illumina scores 48/100 on fundamentals: in the bottom 36% of 503 scored S&P 500 stocks. Its strongest area is Financial Safety (83/100); its weakest is Price Fairness (0/100). It carries 3 warning flags: Weak Spot, Profit Spike, Recent Loss.

Best
Financial 83
Weakest
Price 0
  • Carries a Weak Spot flag
  • Carries a Profit Spike flag
  • Carries a Recent Loss flag

A financially strong, expensively priced stock, but price fairness needs attention.

What looks good
What to watch
Mkt capUS$ 35.6b#293 of 503 in the S&P 500EPSUS$ 5.36P/E40.1×✗ vs sector median 29.6×P/B13.4×✗ vs sector median 3.7×Div yieldNo dividends paidBottom 9% in the S&P 50052w range · 64% of range106.12309.35
as of 31 Oct 2026

Nearby peers

Ranks #41 of 60 in Healthcare by score

#1Universal Health Services79#39Vertex Pharmaceuticals50#40Align Technology48
#41Illumina48
#42Johnson & Johnson48#43CVS Health45

One-Minute Summary

Why Illumina scores 48

A financially strong, expensively priced stock, but price fairness needs attention.

What looks good
What to watch

Business Strength

30
Why 30?
Pillar score: (1 + 1 + 0 + 1 + 0) = 3 of 10 points → 30
Return on Equity (ROE)33%Okay4-Year Revenue Growth+0%/yrOkay4-Year Profit Growthn/m (loss-making)WeakNet Profit Margin20%OkayQuarterly Momentum+5%Weak
Show 3 charts

Net Profit & Equity, with ROE

Net Profit ↑ +177.1%Equity ↓ -53.4%ROE % 33.4%
Net ProfitEquityROE %
-1.2b-1.2b850m895m5.7b2.4b2.7b2.7b202320242025TTM-20.2%-51.5%31.2%33.4%

Revenue & Net Profit, with Net Margin

Revenue → +0.8%Net Profit ↑ +177.1%Net Margin % 19.7%
RevenueNet ProfitNet Margin %
4.5b4.4b4.3b4.5b-1.2b-1.2b850m895m202320242025TTM-25.8%-28%19.6%19.7%

Sales have been roughly flat for 4 years: the business isn't really growing, just maintaining.

The company lost money in recent years: the bars below zero are losses, not profits.

Recent Quarters: Revenue & Net Profit (the last 8 quarters, scored)

Revenue ↑ +7.3%Net Profit ↓ -70.6%Net Margin % 17.9%
RevenueNet ProfitNet Margin %
1.1b1.1b1.0b1.1b1.1b1.2b1.1b1.2b705m186m131m235m150m334m134m207mQ3'24Q4'24Q1'25Q2'25Q3'25Q4'25Q1'26Q2'2665.3%16.8%12.6%22.2%13.8%28.8%12.3%17.9%
▲▲▲▲▼▲▬▼

Sales have stayed roughly flat over the last 8 quarters.

Profit fell about 70.6% over the last 8 quarters.

Why 83?
Pillar score: (1 + 2 + 2) = 5 of 6 points → 83
Debt-to-Equity1×OkayCurrent Ratio1.8×StrongInterest Coverage11.6×Strong
Show 2 charts

Debt vs Equity, with D/E ratio

Total Debt ↑ +12.5%Equity ↓ -53.4%D/E 1×
Total DebtEquityD/E
2.3b2.6b2.6b2.5b5.7b2.4b2.7b2.7b202320242025TTM0.4×1.1×0.9×1×

Borrowings have stayed roughly level: manageable, as long as profits stay healthy.

Short-term assets vs bills, with Current Ratio

Current Assets ↑ +4.9%Current Liabilities → -0.3%Current Ratio 1.7×
Current AssetsCurrent LiabilitiesCurrent Ratio
2.6b2.7b3.3b2.7b1.6b1.5b1.6b1.6b202320242025TTM1.7×1.8×2.1×1.7×
Why 75?
Pillar score: (0 + 2 + 2 + 2) = 6 of 8 points → 75
Dividend QualityNo dividends paidWeak
Payout ratio: 0%
Operating Cash FlowPositive & growingStrongFree Cash FlowPositive & growingStrongCash & Cash EquivalentsGrowing & covers near-term debtStrong
Show 3 charts

Operating vs Free Cash Flow

Operating CF ↑ +157.3%Free CF ↑ +277.7%
Operating CFFree CF
478m837m1.1b1.2b283m709m931m1.1b202320242025TTM

The business generates real cash, and more of it each year: a very healthy sign.

Cash vs Total Debt

Cash ↑ +3.9%Total Debt ↑ +12.5%
CashTotal Debt
1.0b1.1b1.4b1.1b2.3b2.6b2.6b2.5b202320242025TTM

Dividends per Share, with Yield

DPS (cents) → +0%Yield % 0%
DPS (cents)Yield %
000020222023202420250%0%0%0%

Dividends per share have been maintained or raised: management shares the rewards with you.

Why 0?
Pillar score: (0 + 0 + 0) = 0 of 6 points → 0
P/E Ratio40.1×WeakP/B Ratio13.4×WeakPEG Ration/m (growth not measurable)Weak
Show chart

Share Price: Weekly Closes (not part of the score)

US$ 278.17US$ 197.49US$ 116.81Oct '25Feb '26Jun '26Oct '26

The share price is up about 91% over the past year.

Why 50?
Pillar score: (0 + 0 + 2 + 1 + 2 + 1) = 6 of 12 points → 50
Earnings ConsistencyVery bumpyWeakDebt Trend (4yr)RisingWeakShare Count Trend (4yr)-1%/yrStrongInventory vs Sales (4yr)+1.1 pp/yr vs salesOkayAsset Turnover Trend (4yr)+55.4%StrongQuarterly Consistency2 of 4 quarters downOkay
Show chart

Revenue vs Inventory, with Inventory % of Revenue

Revenue → +0.8%Inventory ↑ +4.1%Inv. % of Rev. 13.5%
RevenueInventoryInv. % of Rev.
4.5b4.4b4.3b4.5b587m547m564m611m202320242025TTM13%12.5%13%13.5%
Ranks #41 of 60 in Healthcare by score

Sector peers

#1Universal Health Services79#39Vertex Pharmaceuticals50#40Align Technology48
#41Illumina (you)48
#42Johnson & Johnson48#43CVS Health45

Full Financial History

Every reported figure behind the score, year by year. Download it, or check it against the company's own annual report.

Financial YearRevenueNet ProfitOperating Cash FlowFree Cash FlowCapExCashTotal DebtShort-Term DebtEquityCurrent AssetsCurrent LiabilitiesTotal AssetsTotal LiabilitiesInventoryDividendsReturn on Equity (ROE)Net Profit MarginDebt-to-EquityCurrent RatioInterest CoverageDiv yieldP/E RatioP/B Ratio
2026US$ 4.5bUS$ 895.0mUS$ 1.2bUS$ 1.1bUS$ -161.0mUS$ 1.1bUS$ 2.5bUS$ 499.0mUS$ 2.7bUS$ 2.7bUS$ 1.6bUS$ 6.6bUS$ 3.9bUS$ 611.0m-33%20%1.0×1.8×11.6×---
2025US$ 4.3bUS$ 850.0mUS$ 1.1bUS$ 931.0mUS$ -148.0mUS$ 1.4bUS$ 2.6bUS$ 499.0mUS$ 2.7bUS$ 3.3bUS$ 1.6bUS$ 6.6bUS$ 3.9bUS$ 564.0mUS$ 0.0m31%20%0.9×2.1×11.8×0%24.2×7.6×
2024US$ 4.4bUS$ -1.2bUS$ 837.0mUS$ 709.0mUS$ -128.0mUS$ 1.1bUS$ 2.6bUS$ 499.0mUS$ 2.4bUS$ 2.7bUS$ 1.5bUS$ 6.3bUS$ 3.9bUS$ 547.0mUS$ 0.0m-52%-28%1.1×1.8×-10.8×0%-17.7×9.1×
2023US$ 4.5bUS$ -1.2bUS$ 478.0mUS$ 283.0mUS$ -195.0mUS$ 1.0bUS$ 2.3b-US$ 5.7bUS$ 2.6bUS$ 1.6bUS$ 10.1bUS$ 4.4bUS$ 587.0mUS$ 0.0m-20%-26%0.4×1.7×-13.5×0%-18.5×3.8×